Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PF-06260414 · 1 trial · 1 indication
Quantitative changes in ECG intervals
| Arm | Type | Description |
|---|---|---|
| SAD cohorts 1-7 Experimental Arm | EXPERIMENTAL | - |
| SAD Cohorts 1-7 Placebo Arm | PLACEBO_COMPARATOR | - |
| MAD cohorts 2-6 Experimental Arm | EXPERIMENTAL | - |
| MAD cohorts 2-6 Placebo Arm | PLACEBO_COMPARATOR | - |
| Japanese MAD cohort 7 Experimental arm | EXPERIMENTAL | - |
| Japanese MAD cohort 7 Placebo Arm | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| PF-06260414 | DRUG | Subjects will receive single doses of 1,3,6,30,100,200, 400 mg of PF-06260414 (solution) in a dose escalating format |
| Placebo | DRUG | Subjects will receive single doses of PF-06260414 matching placebo (solution) in a dose escalation format |
Inclusion Criteria: * Healthy male between the ages of 21 and 50 years, inclusive (Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurement, 12 lead ECG and clinical laboratory...
PF-06260414 is an investigational small molecule developed by Pfizer, Inc. (NYSE: PFE). It has been studied in a Phase 1 clinical trial in healthy adult male volunteers rather than in patients with a specific disease. The compound remains in early clinical development.
PF-06260414 is made and developed by Pfizer, Inc., which trades on the New York Stock Exchange under the ticker PFE. Pfizer sponsored the Phase 1 study of the compound conducted in the United States.
PF-06260414 is in Phase 1 clinical development. Its only recorded trial, NCT02070939, was a Phase 1 study that has been completed. The compound is investigational and has not been approved by the FDA for any use.
PF-06260414 has been evaluated in one clinical trial, NCT02070939, titled a study to evaluate safety and tolerability of single and multiple ascending doses of PF-06260414 in healthy Western and Japanese male subjects. The Phase 1 trial enrolled 72 participants, was placebo controlled and double blind, and is completed.
The Phase 1 trial of PF-06260414, NCT02070939, was a randomized, double-blind, placebo-controlled study of single and multiple ascending doses. It enrolled 72 healthy male volunteers aged 21 years and older in the United States, including Western and Japanese subjects, and it has been completed.